Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis

  • Chen, Wen-Jie (Department of Pathology, First Affiliated Hospital of Guangxi Medical University) ;
  • He, De-Shen (Department of Neurology, Seventh Affiliated Hospital of Guangxi Medical University, Wuzhou Worker Hospital) ;
  • Tang, Rui-Xue (Department of Pathology, First Affiliated Hospital of Guangxi Medical University) ;
  • Ren, Fang-Hui (Department of Pathology, First Affiliated Hospital of Guangxi Medical University) ;
  • Chen, Gang (Department of Pathology, First Affiliated Hospital of Guangxi Medical University)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Ki-67 has been widely used as an indicator of cell proliferation in gliomas. However, the role of Ki-67 as a prognostic marker is still undefined. Thus, we conducted a meta-analysis of the published literatures in order to clarify the impact of Ki-67 on survival in glioma cases. Eligible studies were identified in PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, Science Direct and Wiley Online Library with the last search updated on August 31, 2014. The clinical characteristics, overall survival (OS) and progression-free survival (PFS) together with Ki-67 expression at different time points were extracted. A total of 51 studies, covering 4,307 patients, were included in the current meta-analysis. The results showed that overexpression of Ki-67 can predict poor OS (HR=1.66, 95%CI: 1.53-1.80; Z=11.87; p=0.000) and poor PFS (HR=1.67, 95%CI: 1.47-1.91; Z=7.67; p=0.000) in gliomas. Moreover, subgroup analyses also indicated that high level of Ki-67 expression was related to poor OS and PFS in glioma patients regardless of region, pathology type, cut-off value and statistical method. In conclusion, the current meta-analysis revealed that Ki-67 expression might be a predicative factor for poor prognosis of glioma patients, emphasizing its importance as a predictor.

Keywords

References

  1. Abd El Atti RM, Abou Gabal HH, Osman WM, et al (2013). Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagn Pathol, 8, 126. https://doi.org/10.1186/1746-1596-8-126
  2. Armstrong TS, Vera-Bolanos E, Bekele BN, et al (2010). Adult ependymal tumors: prognosis and the M.D. anderson cancer center experience. Neuro Oncol, 12, 862-70. https://doi.org/10.1093/neuonc/noq009
  3. Bowers DC (2003). Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol, 21, 2968-73. https://doi.org/10.1200/JCO.2003.01.017
  4. Bredel M, Piribauer M, Marosi C, et al (2002). High expression of DNA topoisomerase $II\alpha$ and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. European J Cancer, 38, 1343-7. https://doi.org/10.1016/S0959-8049(02)00065-5
  5. Chiang MDH, Ting ML-T, Hsu MDMHAC-Y, et al (2003). MIB-1 and DNA topoisomerase IIa could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol, 119, 715-22. https://doi.org/10.1309/UN4WV65UH94JEWUV
  6. Coons SW, Johnson PC, Pearl DK (1997). The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery, 41, 878-85. https://doi.org/10.1097/00006123-199710000-00021
  7. Dang YW, Zeng J, He RQ, et al (2014). Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 4969-76. https://doi.org/10.7314/APJCP.2014.15.12.4969
  8. Dehghani F, Schachenmayr W, Laun A, et al (1998). Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathologica, 95, 493-504. https://doi.org/10.1007/s004010050830
  9. Donato V, Papaleo A, Castrichino A, et al (2007). Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori, 93, 248.
  10. Ellison DW, Steart PV, Bateman AC, et al (1995). Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry, 59, 413-9. https://doi.org/10.1136/jnnp.59.4.413
  11. Fakhrjou A, Dastranj-Tabrizi A, Ghojazadeh M, et al (2013). Diagnostic value of protein Ki67 (MIB-1) in atypical Pap smears of postmenopausal women. Asian Pac J Cancer Prev, 14, 4815-8. https://doi.org/10.7314/APJCP.2013.14.8.4815
  12. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al (2000). Prognostic factors in intracranial ependymomas in children. J Neurosurg, 93, 605-13. https://doi.org/10.3171/jns.2000.93.4.0605
  13. Habberstad AH, Gulati S, Torp SH (2011). Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol, 6, 43. https://doi.org/10.1186/1746-1596-6-43
  14. Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. https://doi.org/10.7314/APJCP.2013.14.7.4353
  15. Heegaard S, Sommer HM, Broholm H, et al (1995). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer, 76, 1809-13. https://doi.org/10.1002/1097-0142(19951115)76:10<1809::AID-CNCR2820761020>3.0.CO;2-I
  16. Hernandez-Pedro NY, Rangel-Lopez E, Magana-Maldonado R, et al (2013). Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int, 2013, 351031.
  17. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21, 1539-58. https://doi.org/10.1002/sim.1186
  18. Ho DM-T, Hsu C-Y, Wong T-T, et al (2001). A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neuro-Oncol, 54, 77-85. https://doi.org/10.1023/A:1012590505236
  19. Hu X, Miao W, Zou Y, et al (2013). Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Letters, 6, 130-4.
  20. Huang S, Chen G (2014). Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. Scientific World J, 2014, 605236.
  21. Huang T, Jin X, He L, et al (2013). Role of podocalyxin in astrocytoma: clinicopathological and evidence. Oncol Lett, 6, 1390-6.
  22. Jaros E, Perry R, Adam L, et al (1992). Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer, 66, 373. https://doi.org/10.1038/bjc.1992.273
  23. Kanamori M, Kumabe T, Sonoda Y, et al (2008). Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neuro-Oncol, 93, 219-28.
  24. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, et al (2006). Characterization of glioblastomas in young adults. Brain Pathology, 16, 273-86. https://doi.org/10.1111/j.1750-3639.2006.00029.x
  25. Kohler BA, Ward E, McCarthy BJ, et al (2011). Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst, 103, 714-36 https://doi.org/10.1093/jnci/djr077
  26. Kouri FM, Jensen SA, Stegh AH (2012). The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. Scientific World J, 2012, 838916.
  27. Kros JM, Hop WC, Godschalk JJ, et al (1996). Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer, 78, 1107-13. https://doi.org/10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5
  28. Kuo LT, Kuo KT, Lee MJ, et al (2009). Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer, 124, 2872-9. https://doi.org/10.1002/ijc.24303
  29. Laks DR, Masterman-Smith M, Visnyei K, et al (2009). Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells, 27, 980-7. https://doi.org/10.1002/stem.15
  30. Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intl Med, 127, 820-6. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
  31. Li S-W, Qiu X-G, Chen B-S, et al (2009). Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J, 122, 1245-9.
  32. Liu Y, Tang K, Yan W, et al (2013). Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. Neuroscience Letters, 546, 36-41. https://doi.org/10.1016/j.neulet.2013.04.030
  33. Margraf LR, Gargan L, Butt Y, et al (2011). Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas-an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol, 13, 767-74. https://doi.org/10.1093/neuonc/nor041
  34. McKeever PE, Strawderman MS, Yamini B, et al (1998). MIB- 1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol, 57, 931-6. https://doi.org/10.1097/00005072-199810000-00005
  35. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al (1994). Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery, 34, 674-9. https://doi.org/10.1227/00006123-199404000-00016
  36. Nabika S, Kiya K, Satoh H, et al (2010). Prognostic significance of expression patterns of EGFR family, p21 and p27 in high-grade astrocytoma. Hiroshima J Med Sci, 59, 65-70.
  37. Nazarenko I, Hede SM, He X, et al (2012). PDGF and PDGF receptors in glioma. Ups J Med Sci, 117, 99-112. https://doi.org/10.3109/03009734.2012.665097
  38. Neder L, Colli B, Machado H, et al (2003). MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol, 23, 262-70. https://doi.org/10.1046/j.1440-1789.2003.00510.x
  39. Okita Y, Narita Y, Miyakita Y, et al (2012). Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol, 29, 192-200. https://doi.org/10.1007/s10014-012-0084-2
  40. Park KJ, Kang SH, Park DH, et al (2012). Usefulness of thallium-201 SPECT for prediction of early progression in low-grade astrocytomas diagnosed by stereotactic biopsy. Clin Neurol Neurosurg, 114, 223-9. https://doi.org/10.1016/j.clineuro.2011.10.023
  41. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  42. Phi JH, Wang KC, Park SH, et al (2012). Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. J Neurooncol, 106, 619-26. https://doi.org/10.1007/s11060-011-0699-x
  43. Pollack IF, Campbell JW, Hamilton RL, et al (1997). Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer, 79, 849-56. https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4<849::AID-CNCR23>3.0.CO;2-Z
  44. Pollack IF, Hamilton RL, Burnham J, et al (2002). Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery, 50, 1238-45.
  45. Preusser M, Hoeftberger R, Woehrer A, et al (2012). Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European organization for research and treatment of cancer brain tumor group. Histopathology, 60, 885-94. https://doi.org/10.1111/j.1365-2559.2011.04134.x
  46. Preusser M, Wolfsberger S, Czech T, et al (2005). Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol, 124, 543-9. https://doi.org/10.1309/PP2G5GAAFKV82DTG
  47. Qiang J, Wei Z, Xiao-Guang Q, et al (2011). Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chinese Med J Beijing, 124, 2584.
  48. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al (2001). The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol, 55, 195-204. https://doi.org/10.1023/A:1013845004294
  49. Ritter AM, Hess KR, McLendon RE, et al (1998). Ependymomas: MIB-1 proliferation index and survival. J Neurooncol, 40, 51-7. https://doi.org/10.1023/A:1006082622699
  50. Rodriguez-Pereira C, Suarez-Penaranda J, Vazquez-Salvado M, et al (2000). Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study. J Neurosurg Sci, 44, 203-9; discussion 9-10.
  51. Shen C, Yang L, Yuan X (2011). Endothelin B receptor expression in human astrocytoma: association with clinicopathological variables and survival outcomes. Int J Neurosci, 121, 626-31. https://doi.org/10.3109/00207454.2011.602808
  52. Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev, 13, 5155-9. https://doi.org/10.7314/APJCP.2012.13.10.5155
  53. Tian B, Zhang Y, Zhang J (2014). Periostin is a new potential prognostic biomarker for glioma. Tumour Biol, 35, 5877-83. https://doi.org/10.1007/s13277-014-1778-3
  54. Torp S, Helseth E, Dalen A, et al (1992). Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochirurgica, 117, 182-6. https://doi.org/10.1007/BF01400618
  55. Tove L-L, Hansson HA, Stein S, et al (2012). Prognostic value of histological features in diffuse astrocytomas WHO grade II. Interl J Clin Experimental Pathol, 5, 152.
  56. Uematsu M, Ohsawa I, Aokage T, et al (2005). Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol, 72, 231-8. https://doi.org/10.1007/s11060-004-2353-3
  57. Watanabe Y, Yamasaki F, Kajiwara Y, et al (2010). Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol, 100, 449-57. https://doi.org/10.1007/s11060-010-0201-1
  58. Wen PY, Kesari S (2008). Malignant gliomas in adults. New England J Med, 359, 492-507. https://doi.org/10.1056/NEJMra0708126
  59. Wessels PH, Hopman AH, Kubat B, et al (2003). Proliferation and aneusomy predict survival of young patients with astrocytoma grade II. Br J Cancer, 89, 128-34. https://doi.org/10.1038/sj.bjc.6601067
  60. Westermark B (2012). Glioblastoma-a moving target. Ups J Med Sci, 117, 251-6. https://doi.org/10.3109/03009734.2012.676574
  61. Yang P, Wang Y, Peng X, et al (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 113, 259-66. https://doi.org/10.1007/s11060-013-1103-9
  62. Yoshida Y, Nakada M, Harada T, et al (2010). The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol, 98, 41-7. https://doi.org/10.1007/s11060-009-0064-5
  63. Yue Q, Zhang X, Ye HX, et al (2014). The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol, 116, 251-9. https://doi.org/10.1007/s11060-013-1314-0
  64. Zamecnik J, Snuderl M, Eckschlager T, et al (2003). Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Modern Pathol, 16, 980-91. https://doi.org/10.1097/01.MP.0000087420.34166.B6
  65. Zawrocki A, Izycka-Swieszewska E, Papierz W, et al (2011). Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Folia Neuropathol, 49, 94-102.
  66. Zhao S, Wu J, Wang C, et al (2013). Intraoperative fluorescenceguided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One, 8, e63682. https://doi.org/10.1371/journal.pone.0063682
  67. Zhong D, Li X, Zhang G (2001). Multivariate analysis of the parameters related to prognosis of astrocytoma. Zhonghua Bing Li Xue Za Zhi Chinese J Pathol, 30, 345-9.

Cited by

  1. Expression of Vimentin and Ki-67 Proteins in Cervical Squamous Cell Carcinoma and their Relationships with Clinicopathological Features vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4271
  2. Central, Extraventricular and Atypical Neurocytomas: a Clinicopathologic Study of 35 Cases from Pakistan Plus a Detailed Review of the Published Literature vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1565
  3. Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas vol.53, pp.6, 2016, https://doi.org/10.1177/0300985816644301
  4. (Pro)renin receptor is crucial for glioma development via the Wnt/β-catenin signaling pathway vol.127, pp.4, 2017, https://doi.org/10.3171/2016.9.JNS16431
  5. Value of the visual and semiquantitative analysis of carbon-11-methionine PET/CT in brain tumors’ recurrence versus post-therapeutic changes vol.38, pp.12, 2017, https://doi.org/10.1097/MNM.0000000000000754
  6. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma vol.39, pp.9, 2017, https://doi.org/10.1177/1010428317724282
  7. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma pp.17437555, 2019, https://doi.org/10.1111/ajco.12826
  8. Prognostic Value of microRNA-133a Expression and Its Clinicopathologic Significance in Non-Small Cell Lung Cancer: A Comprehensive Study Based on Meta-Analysis and the TCGA Database vol.41, pp.12, 2018, https://doi.org/10.1159/000492343
  9. Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma pp.1573-7373, 2018, https://doi.org/10.1007/s11060-018-03050-6
  10. Ki-67 expression in mature B-cell neoplasms: a flow cytometry study vol.64, pp.6, 2018, https://doi.org/10.1590/1806-9282.64.06.525
  11. CEST-MRI for glioma pH quantification in mouse model: Validation by immunohistochemistry vol.31, pp.11, 2018, https://doi.org/10.1002/nbm.4005
  12. Radiomics based on multicontrast MRI can precisely differentiate among glioma subtypes and predict tumour-proliferative behaviour pp.1432-1084, 2018, https://doi.org/10.1007/s00330-018-5704-8
  13. Imaging characteristics of cerebral extraventricular neurocytoma with pathological correlation pp.1573-7373, 2018, https://doi.org/10.1007/s11060-018-2952-z
  14. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma vol.9, pp.1, 2018, https://doi.org/10.1038/s41467-018-05373-4
  15. Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I–IV astrocytic brain tumors vol.144, pp.7, 2018, https://doi.org/10.1007/s00432-018-2645-1
  16. Standard diffusion-weighted, diffusion kurtosis and intravoxel incoherent motion MR imaging of sinonasal malignancies: correlations with Ki-67 proliferation status vol.28, pp.7, 2018, https://doi.org/10.1007/s00330-017-5286-x
  17. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival vol.21, pp.2, 2018, https://doi.org/10.1093/neuonc/noy169